Figure 1.
Dosing of subcutaneous (s.c.) cladribine according to individual total lymphocyte count.
Cycle 1
At week 1 cladribine 10 mg s.c. is administered on three consecutive days (four days in patients >90 kg body weight).
Subsequent administration in week 5 is based on total lymphocyte count detected in week 4:
If lymphocytes are >1 × 109/µl: Administer 10 mg s.c. on three consecutive days.
If lymphocytes are 0.8–1 × 109/µl: Administer 10 mg s.c. on two consecutive days.
If lymphocytes are 0.5–0.8 (×109): Administer 10 mg s.c. on one day.
If lymphocytes are below 0.5 (×109): Administer no further dose.
Cycle 2
At week 48 total lymphocyte count is being tested. If total lymphocyte count is ≥1 × 109/µl, cladribine s.c. will be administered identically to weeks 1 and 5 above.
If total lymphocyte count is ≤1 × 109/µl, cladribine s.c. will be administered as in week 5 only, with no further drug administrations in week 53.